✦ LIBER ✦

Long term follow-up of patients with acute myelogenous leukemia who received the daunorubicin, vincristine, and cytosine arabinoside regimen

✍ Scribed by Yves Beguin; Brieuc Sautois; Patricia Forget; Jean Bury; Georges Fillet

Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 66 KB
Volume: 79
Category: Article
ISSN: 0008-543X
DOI: 10.1002/(sici)1097-0142(19970401)79:7<1351::aid-cncr12>3.0.co;2-z

No coin nor oath required. For personal study only.

✦ Synopsis

In 1985, the authors published a study of acute myelogenous leuke-

📜 SIMILAR VOLUMES

Long-term follow-up of three randomized

Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia

✍ Ellin Berman; Peter Wiernik; Ralph Vogler; Enrique Vélez-Gárcia; Alfred Bartoluc 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

BACKGROUND. Most clinical trials for acute leukemia have reported results after

Long-term survival of patients with acut

Long-term survival of patients with acute myeloid leukemia : A third follow-up of the Fourth International Workshop on Chromosomes in Leukemia

✍ Clara D. Bloomfield; Cynthia Shuma; Linda Regal; Preben P. Philip; Dieter K. Hos 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 284 KB 👁 2 views

## Background: In 1982, the fourth international workshop on chromosomes in leukemia reviewed data prospectively collected on 716 patients with acute myeloid leukemia (aml) diagnosed between 1980 and 1982. the present study examined the extended follow-up on these patients. ## Methods: The analys

Long-term follow-up of patients with new

Long-term follow-up of patients with newly diagnosed acute myeloid leukemia treated at the University of Texas M. D. Anderson Cancer Center

✍ Elihu Estey; Marcos deLima; Sara Strom; Sherry Pierce; Emil J Freireich; Michael 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 2 views

## RESULTS. Because failure rates declined to relatively low levels after a first or later complete remission of ¢3 years' duration, such patients comprised a ''potentially Departments of Hematology and Epidemiology, cured'' cohort. The criterion for entry into this cohort was fulfilled by 215 pat